Get on the Waiting List For our No.1 Stock Suggestion!

    EXPLORE THE FRONTIERS With Breakthrough Science!

    Now that the public has a heightened awareness of the unfortunate side effects of traditional medications, the charge to deliver new solutions has brought novel treatments. As a result, once-maligned and over-regulated treatments are now offering the potential to change lives for the better.

    Some of the most exciting developments are in the domain of mood disorders, such as depression and anxiety. As an alternative to older medications that tend to suppress the patient’s personality, psychedelic medicine can actually enhance their personality. Oftentimes, the patient will report a highly positive and life-changing experience.

    This is not the illegal “drug trip” of street drugs, but a pathway to a “better you” that we can all access. Psychedelic medicines derived from psilocybin and ketamine have the potential to help patients break down psychological walls and reconnect with themselves and those they care about.

    In a time when shelter-in-place orders are disconnecting people from their family and friends, connections are more critical than ever. There’s actually a phenomenon now known as “pandemic anxiety,” where the population’s mental health is reaching the breaking point because of the coronavirus.

    How bad is it getting? One recent study of college students found that since the spread of the pandemic, 20% of college students are more depressed, 11% are more anxious, and 16% report being more lonely. When your circumstances are unpredictable and out of your control, these issues are bound to come to the surface.

    Leading global institutions have taken the lead in researching psychedelic medicine, and their findings indicate that psilocybin-assisted therapy could be a revolutionary treatment for depression, anxiety, and even addiction to alcohol and tobacco. That’s right: psychedelics are going mainstream, and Big Pharma will need to adapt to the changing scientific landscape.

    The medical community is paying close attention, and so are investors and insiders who see what’s coming down the pipeline. One of the most engaged companies today is Champignon Brands (CSE: SHRM, OTC: SHRMF), which specializes in identifying, commercializing and delivering psychedelic-based treatments.

    Dr. Roger McIntyre. Courtesy: University of Toronto

    CEO Roger McIntyre is a world-renowned expert in the use of psychedelics, such as psilocybin and ketamine, to treat depression and anxiety. Dr. McIntyre had the vision to implement and develop Canada’s first-ever treatment center, the Canadian Rapid Treatment Centre of Excellence, to provide rapid-onset treatments for people with mood disorders.

    93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

    Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

    Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

      Dr. McIntyre’s accomplishments are numerous:

      • He’s published over 600 articles on the topic of mood disorders
      • He authored an extensive number of books and chapters
      • He’s a top-ranked expert in the area of depression
      • He’s named one of the World’s Most Influential Scientific Minds each year from 2014 to 2019 by Clarivate Analytics

      Today, Champignon not only has the expertise of Dr. McIntyre, but also the only Health Canada-approved clinic to conduct randomized controlled trials for psilocybin and the largest depression-focused center of its type in the world. And since the Canadian Rapid Treatment Centre of Excellence is the leading Canadian ketamine clinic operator, Champignon is easily outpacing its peers in the areas of research and development.

      Keep your eyes on Champignon Brands.

      Prosperous Regards,
      Kenneth Ameduri
      Chief Editor, CrushTheStreet.com

      Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!

      Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!


        Legal Notice:

        This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

        Never base any decision off of our emails. CrushTheStreet.com stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish.   Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Future Money Trends LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign.  Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. Please review our entire disclaimer at CrushTheStreet.com/disclaimer.